ARMS2, ALA69SER

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
0120122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
We designed this meta-analysis to pool studies which have analyzed both CFH (Y402H or I62V) and ARMS2 A69S in the same samples to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Though anti-vascular endothelial growth factor therapy has become the standard treatment for exudative age-related macular… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2017
2017
Photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (VEGF) agents is currently the… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
2017
Review
2017
To investigate whether the severity of the condition in the untreated fellow eye is a predictive factor for the response to… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2016
2016
PURPOSE To investigate risk factors associated with developing polypoidal choroidal vasculopathy (PCV) lesions in the unaffected… (More)
Is this relevant?
Review
2012
Review
2012
PURPOSE To study the association of ARMS2 A69S genotype with the development of exudative age-related macular degeneration (AMD… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?